NCT04671017View on ClinicalTrials.gov

Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

153

Participants

Timeline

Start Date

December 16, 2020

Primary Completion Date

February 26, 2021

Study Completion Date

April 6, 2022

Conditions

SARS-CoV-2 Virus Infection

Interventions

BIOLOGICAL

VLA2001

whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide

Trial Locations (4)

B15 2TH

Queen Elizabeth Hospital, Birmingham

BS1 3NU

University Hospital Bristol and Weston NHS Foundation Trust, Bristol

NE7 7DN

Newcastle University Medical School, Newcastle

SO16 6YD

Southampton NIHR Clinical Research Facility, Southampton

All Listed Sponsors

collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

lead

Valneva Austria GmbH

INDUSTRY

NCT04671017 - Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects | Biotech Hunter | Biotech Hunter